Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. Agilent Technologies
  4. Financial Ratios
Agilent Technologies logo
Agilent Technologies A
$ 174.0 1.39%
report update icon

Quarterly report 2026-Q2
added 06-01-2026

Agilent Technologies Financial Ratios 2025-2006 | A

Brief overview of Agilent Technologies's financial ratios

Current figures are compared with the company's own five-year history for 2021–2025.

The current valuation set is P/E 24.2x (median 29.35x), EV/EBITDA 20.22x (median 23.14x), P/S 4.54x (median 5.37x). The current ratio basket stands about 15.5% below the five-year comparison base. Earnings and risk trends should explain the discount.

At the current P/E, inverse earnings yield is 4.1%, a useful bridge between price and business earnings.

Returns on assets and capital are represented by ROE 19.3%, ROA 10.2%, ROCE 21.9%. Profitability forms a strong profile, with capital and assets producing substantial returns.

Price, earnings and growth produce a PEG of 1.95x. A high value reduces the cushion if growth slows.

The cash conversion cycle lengthened from 110.8 days to 122.8 days, or 12 days. More cash is tied up in operations.

Overall assessment

Agilent Technologies combines solid capital returns with a discount to its own history. The main question is whether earnings and growth are sustainable.

Annual Financial Ratios Agilent Technologies

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006

P/E

 24.2 29.6 27.6 29.3 34.7 50.1 23.7 73.5 32.6 31.0 34.7 28.2 18.0 8.3 9.2 11.4 -150.7 13.8 0.0 -

P/S

 4.5 5.9 5.0 5.4 6.6 6.7 4.9 4.7 5.0 3.4 3.4 2.0 1.9 1.4 1.4 1.4 1.0 - - -

EPS

 4.6 4.4 4.2 4.2 4.0 2.3 3.4 1.0 2.1 1.4 1.2 1.6 2.1 3.3 2.9 2.0 -0.1 1.9 1.6 -

EV (Enterprise Value)

 35.7 B 42.7 B 37.5 B 41 B 45.8 B 39.3 B 28.7 B 24.9 B 23.2 B 15.6 B 15.2 B 16.7 B 15.8 B 12.5 B 10.5 B 11.6 B 7.29 B 12.6 B -1.83 B -2.26 B

EBITDA per Share

 6.22 6.02 5.51 6.47 5.49 3.75 3.75 3.55 3.27 2.64 2.33 3.65 3.88 4.08 3.82 2.21 0.6 2.74 1.97 M -

EV/EBITDA

 20.2 24.5 23.1 21.2 27.4 32.0 22.4 20.0 20.5 16.2 17.5 11.5 9.9 6.7 6.0 15.1 34.9 12.7 -2.4 -

PEG

 1.95 2.52 2.5 1.87 2.05 -1.59 0.1 -1.37 0.65 1.77 -1.78 -0.95 -0.5 0.62 0.15 - - - - -

P/B

 4.7 6.5 5.8 6.9 7.8 7.4 5.3 5.1 4.6 3.4 3.3 2.7 2.5 1.8 2.2 2.4 1.9 3.7 - -

P/CF

 20.2 21.8 19.3 28.1 28.3 44.9 29.3 25.5 31.3 21.9 35.4 28.1 13.7 9.2 8.7 10.9 11.5 12.7 0.0 -

ROE %

 19.33 21.85 21.21 23.64 22.45 14.75 22.56 6.91 14.15 10.88 9.62 9.51 13.69 22.24 23.45 21.19 -1.24 27.08 19.73 -

ROA %

 10.24 10.88 11.52 11.91 11.30 7.47 11.33 3.70 8.12 5.92 5.36 4.65 6.78 10.94 11.17 7.05 -0.41 9.89 - -

ROCE %

 21.94 25.23 23.10 30.50 25.00 10.37 12.76 12.59 11.74 8.97 8.03 9.10 10.47 12.95 14.83 17.53 1.88 31.07 18.06 -

Current Ratio

 2.1 2.0 2.2 2.0 2.0 2.3 1.5 3.3 3.3 3.8 3.8 3.2 3.1 2.4 3.0 1.5 1.5 1.6 - -

DSO

 73.8 73.3 72.0 68.7 63.8 71.0 65.7 57.6 59.1 54.8 54.8 51.4 48.4 49.1 47.5 49.1 55.6 - - -

DIO

 110.3 122.9 112.1 109.1 97.1 105.0 105.1 104.6 101.7 97.0 98.9 115.5 119.8 113.7 106.2 92.0 99.9 45.7 - -

DPO

 61.3 58.8 54.1 59.9 50.1 51.6 54.8 55.7 54.0 46.8 51.0 51.2 48.6 51.7 55.8 58.5 51.3 21.8 - -

Operating Cycle

 184.1 196.2 184.1 177.7 161.0 176.0 170.9 162.2 160.8 151.8 153.7 166.9 168.2 162.9 153.7 141.1 155.5 45.7 - -

Cash Conversion Cycle

 122.8 137.4 130.0 117.8 110.8 124.4 116.1 106.5 106.9 105.1 102.7 115.7 119.7 111.2 97.8 82.6 104.2 23.9 - -

All numbers in USD currency

Quarterly Financial Ratios Agilent Technologies

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q3 2010-Q2 2010-Q1 2009-Q3

EPS

 1.2 1.08 1.08 - 1.18 1.12 1.12 - 0.97 1.19 1.19 0.38 1.02 1.02 0.94 - - 0.92 0.94 - 0.87 0.71 0.64 1.61 0.64 0.33 1.58 2.78 0.61 0.57 -0.99 0.38 0.74 0.64 0.52 1.57 0.55 0.51 0.37 1.03 0.38 0.28 0.19 0.78 0.33 0.26 0.59 1.44 0.44 0.42 0.52 1.49 0.5 0.48 0.66 2.09 0.7 0.73 0.56 2.08 0.95 0.58 0.59 0.31 0.23 -0.06

EBITDA per Share

 1.89 1.48 1.48 - 1.36 1.57 1.57 - 1.23 1.52 1.52 1.16 1.76 1.42 1.52 - - 1.37 1.32 - 1.61 1.1 0.95 2.52 1.25 0.48 0.96 2.7 1.06 0.76 0.87 2.53 1.01 0.73 0.81 2.39 0.97 0.73 0.67 1.91 0.85 0.52 0.54 1.67 0.83 0.43 0.66 1.92 0.97 0.43 0.9 2.74 1.24 0.76 0.96 3.01 1.13 0.94 0.79 2.73 1.17 0.86 0.72 658 K 382 K 0.35

ROE %

 18.86 19.38 20.24 15.83 21.45 18.17 18.12 12.84 12.84 18.07 12.45 17.94 21.29 22.06 22.17 16.68 16.68 20.69 19.40 13.41 23.61 22.35 20.46 26.41 34.68 34.62 36.33 19.25 3.41 4.53 5.16 16.15 24.01 22.49 21.42 20.50 17.93 17.23 15.98 14.47 12.82 12.56 12.50 14.60 17.41 17.52 18.05 17.82 18.45 18.85 19.37 21.14 25.48 26.99 28.77 29.45 32.19 35.16 34.88 36.40 23.73 19.12 13.72 4.12 3.05 -0.76

ROA %

 10.10 10.18 10.47 8.09 11.27 9.56 9.69 7.02 7.02 9.82 6.64 9.38 10.96 11.14 10.85 8.11 8.11 10.13 9.58 6.61 11.77 11.32 10.37 13.93 18.04 18.00 18.85 9.55 1.68 2.42 2.89 8.70 13.30 12.62 12.17 11.70 9.99 9.51 8.73 7.91 7.09 6.98 6.98 7.97 8.93 8.80 8.92 8.77 9.12 9.34 9.61 10.45 12.56 13.30 14.16 14.04 15.11 16.45 16.23 16.09 9.50 6.89 4.40 1.39 1.04 -0.29

ROCE %

 21.47 22.11 23.24 18.13 24.33 21.08 21.46 15.22 15.22 21.85 15.64 22.94 27.57 27.78 27.94 20.65 20.65 25.99 23.40 16.57 27.80 25.72 22.52 23.05 26.38 26.40 28.81 28.91 28.72 28.79 28.82 28.55 26.76 26.11 25.70 24.74 22.33 21.61 20.54 19.42 18.03 18.04 17.52 17.08 14.88 13.90 13.11 14.89 20.90 22.90 25.15 27.12 30.75 31.50 33.26 33.56 34.93 36.24 36.63 34.40 22.67 19.78 13.56 5.87 3.63 -0.04

Current Ratio

 2.2 2.2 2.2 2.1 2.1 2.0 2.0 2.0 - 2.3 - 2.1 2.1 2.1 2.0 2.0 - 2.0 2.0 2.0 1.9 2.0 2.0 2.0 2.0 2.0 2.3 2.0 2.0 2.0 2.1 2.2 2.2 2.2 2.2 2.4 2.4 2.4 2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.3 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.7 1.9 1.9 1.9 1.4 1.5 1.5 1.6

DSO

 75.1 77.2 76.3 - 71.1 72.1 72.0 - 37.4 35.6 36.9 74.8 74.5 69.2 71.1 - - 66.0 66.6 - 66.0 64.0 67.4 24.6 69.6 63.4 62.6 22.4 66.6 62.0 58.4 20.2 60.7 55.0 58.9 20.1 59.3 55.5 55.4 18.6 55.1 55.8 54.3 18.4 54.5 68.9 66.8 19.0 56.6 69.3 48.1 16.2 49.7 45.1 48.5 16.5 48.9 46.8 51.5 16.1 46.4 44.9 - - - -

DIO

 116.0 113.4 111.6 - 107.9 116.3 114.9 - 65.2 62.8 65.2 97.9 126.9 114.0 114.5 - - 103.5 101.8 - 102.4 99.0 102.6 36.4 113.3 110.2 105.3 35.9 106.5 103.2 104.8 34.8 105.7 95.7 104.2 34.5 101.3 101.0 101.0 32.8 96.9 102.0 97.9 33.0 98.5 153.9 152.3 34.7 103.3 146.4 120.1 39.9 122.2 108.7 117.0 38.4 111.1 101.4 110.0 36.0 102.6 93.1 85.4 89.1 92.3 -

DPO

 65.7 64.5 62.8 - 57.8 63.8 63.4 - 30.8 29.7 27.5 41.9 55.1 54.9 63.0 - - 55.1 54.2 - 53.6 49.9 49.1 17.9 53.0 50.9 52.9 18.7 55.5 51.8 53.6 18.8 57.2 49.4 53.0 18.3 53.7 49.6 47.1 15.8 46.7 48.0 47.7 17.0 50.8 67.0 67.1 18.3 54.4 68.6 50.5 16.2 49.5 46.5 53.2 17.5 50.5 50.7 59.5 18.9 53.9 54.7 56.8 55.2 46.6 -

Operating Cycle

 - - 187.9 - 179.1 - 186.9 - - - - - - 183.3 85.3 - - 169.5 168.4 - 168.4 162.9 170.0 60.9 182.9 173.5 168.0 58.2 173.1 165.2 163.2 54.9 166.4 150.7 163.1 54.6 160.6 156.5 156.4 51.5 152.0 157.8 152.2 51.4 153.1 222.8 219.0 53.7 159.9 215.7 168.3 56.1 171.9 153.8 165.4 55.0 160.0 148.2 161.5 52.0 149.0 - - - - -

Cash Conversion Cycle

 - - 125.2 - 121.3 - 123.4 - - - - - - 128.4 57.0 - - 114.4 114.2 - 114.8 113.0 120.8 43.0 129.9 122.6 115.1 39.5 117.6 113.3 109.7 36.1 109.2 101.3 110.1 36.3 106.9 106.9 109.3 35.6 105.3 109.8 104.5 34.4 102.2 155.8 152.0 35.5 105.6 147.1 117.7 39.9 122.3 107.2 112.3 37.5 109.5 97.5 102.0 33.1 95.1 - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Agilent Technologies, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Organovo Holdings Organovo Holdings
ONVO
 		- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
 		- -16.95 % $ 1.54 M usaUSA
PerkinElmer PerkinElmer
PKI
 		- -0.91 % $ 14.7 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
 		- - $ 2.69 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
 		- -8.98 % $ 14.8 K usaUSA
Biomerica Biomerica
BMRA
 		$ 1.8 0.82 % $ 5.25 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
 		$ 4.15 1.72 % $ 384 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
 		$ 1.99 0.73 % $ 597 M usaUSA
Neuronetics Neuronetics
STIM
 		$ 1.89 0.23 % $ 125 M usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
 		$ 302.0 1.0 % $ 15 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
 		- - $ 21.2 M usaUSA
Surmodics Surmodics
SRDX
 		- - $ 608 M usaUSA
Biodesix Biodesix
BDSX
 		$ 23.99 0.18 % $ 181 M usaUSA
Heska Corporation Heska Corporation
HSKA
 		- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
 		- -20.0 % $ 1.06 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
 		$ 2.66 0.37 % $ 86.3 K usaUSA
Precipio Precipio
PRPO
 		$ 22.25 1.0 % $ 35.7 M usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
 		$ 14.61 0.33 % $ 154 M chinaChina
Bioventus Bioventus
BVS
 		$ 13.5 0.22 % $ 899 M usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
 		$ 11.51 4.01 % $ 391 M israelIsrael
CareDx, Inc CareDx, Inc
CDNA
 		$ 64.69 0.31 % $ 3.45 B usaUSA
Celcuity Celcuity
CELC
 		$ 59.9 0.1 % $ 2.8 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
 		$ 0.76 11.61 % $ 1.01 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
 		$ 33.11 0.7 % $ 960 M usaUSA
Danaher Corporation Danaher Corporation
DHR
 		$ 224.69 0.83 % $ 160 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
 		$ 5.45 2.21 % $ 21.7 M israelIsrael
DexCom DexCom
DXCM
 		$ 83.47 0.6 % $ 32.6 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
 		$ 21.01 0.31 % $ 647 M usaUSA
Syneos Health Syneos Health
SYNH
 		- - $ 4.46 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
 		- -34.28 % $ 263 K israelIsrael
Renalytix AI plc Renalytix AI plc
RNLX
 		- 5.66 % $ 22.7 M britainBritain
Chembio Diagnostics Chembio Diagnostics
CEMI
 		- 0.22 % $ 16.8 M usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
 		- -1.84 % $ 15.3 M usaUSA
T2 Biosystems T2 Biosystems
TTOO
 		- -39.35 % $ 313 K usaUSA
DermTech DermTech
DMTK
 		- -11.32 % $ 2.94 M usaUSA
Guardant Health Guardant Health
GH
 		$ 162.99 0.56 % $ 20.4 B usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
 		- - $ 1.49 B usaUSA
Akumin Akumin
AKU
 		- -17.87 % $ 25.9 M canadaCanada
Accelerate Diagnostics Accelerate Diagnostics
AXDX
 		- -61.36 % $ 2.46 M usaUSA
Quotient Limited Quotient Limited
QTNT
 		- -11.32 % $ 1.1 M schweizSchweiz
Biocept Biocept
BIOC
 		- -13.05 % $ 7.29 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
 		$ 262.01 0.51 % $ 45 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
 		$ 168.97 2.82 % $ 13.3 B irlandaIrlanda
Illumina Illumina
ILMN
 		$ 271.76 0.22 % $ 42.1 B usaUSA
BioNano Genomics BioNano Genomics
BNGO
 		$ 1.37 0.74 % $ 7.46 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
 		$ 317.34 1.18 % $ 26.4 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
 		$ 100.0 0.03 % $ 6.75 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
 		$ 616.63 1.11 % $ 17.8 B usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
 		$ 4.78 1.16 % $ 3.76 M usaUSA